Ken Griffin Argenx Se Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $18.3 Million - $21.2 Million	-51,200 Reduced 60.52%	33,400 $13.2 Million
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $15.2 Million - $22.7 Million	44,800 Added 112.56%	84,600 $32.2 Million
Q3 2023 Nov 14, 2023	SELL	$369.35 - $548.43 $1.74 Million - $2.58 Million	-4,700 Reduced 10.56%	39,800 $19.6 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $2.27 Million - $2.66 Million	6,300 Added 16.49%	44,500 $17.3 Million
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $3.44 Million - $4.16 Million	10,300 Added 36.92%	38,200 $14.2 Million

Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $4.55 Million - $5.35 Million	13,300 Added 91.1%	27,900 $10.6 Million
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $4.56 Million - $5.26 Million	-13,300 Reduced 47.67%	14,600 $5.16 Million

356

31.3M

212K

210K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $23.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.